aTyr Pharma, Inc.

Rentabilité pendant six mois: +33.33%
Rendement des dividendes: 0%
Secteur: Healthcare

5.2 $

0 $ 0%
1.72 $
5.5 $

Min./max. pendant un an

Calendrier de promotion aTyr Pharma, Inc.

Les principaux paramètres

Devise
usd
Industrie
Biotechnology
Isin
US0021202025
La monnaie du rapport
usd
Secteur
Health Care
Site web
Temps d'introduction en bourse
2015-05-07

Grade

Sous-estimation
Nom Signification Grade
P/S 1143.94 1
P/BV 3.85 4
P/E 0 0
Efficacité
Nom Signification Grade
ROA -58.88 0
ROE -79.69 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement des dividendes 0 0
DSI 0 0
La croissance moyenne des dividendes 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.2001 10
Debt/Ratio 0.1372 10
Debt/Equity 0.3866 10
Pouls de croissance
Nom Signification Grade
Revenus, milliards, % -97.76 0
Ebitda, % 353.22 10
EPS, % -41.45 0

Prix

Prix Min. Max. Changement Changements dans l'industrie Changements dans l'index
Hier 5.2 $ 0 $ 0 $ 0 % 0 % 0 %
Semaine 5.4 $ 0 $ 0 $ -3.61 % 0 % 0 %
Mois 3.75 $ 0 $ 0 $ +38.67 % 0 % 0 %
3 mois 2.97 $ 3 $ 5.5 $ +75.08 % 0 % 0 %
Six mois 3.9 $ 2.62 $ 5.5 $ +33.33 % 0 % 0 %
Année 1.85 $ 1.72 $ 5.5 $ +181.08 % 0 % 0 %
3 ans 1.46 $ 1.46 $ 5.5 $ +356.16 % 0 % 0 %
5 ans 1.46 $ 1.46 $ 5.5 $ +356.16 % 0 % 0 %
10 ans 1.46 $ 1.46 $ 5.5 $ +356.16 % 0 % 0 %
Année à ce jour 3.53 $ 2.62 $ 5.5 $ +47.31 % 0 % 0 %

Entreprises similaires



La gestion de l'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Sanjay S. Shukla M.D., M.S. President, CEO & Director 1972 (53 années)
Ms. Jill M. Broadfoot Chief Financial Officer 1962 (63 années)
Ms. Nancy E. Denyes Krueger General Counsel & Corporate Secretary 1968 (57 années)
Xiang-Lei Yang Ph.D. Founder
Dr. Jayant Aphale MBA, Ph.D. Vice President of Technical Operations 1960 (65 années)
Ms. Ashlee Dunston Director of Investor Relations & Corporate Communications
Mr. Peter Villiger Vice President of Corporate Development
Ms. Danielle Campbell VP of Human Resource
Dr. Leslie Nangle Ph.D. Vice President of Research
Dr. Ying J. Buechler Ph.D. Executive Director of Biologics Development & Manufacturing

Informations sur l'entreprise

Adresse: United States, San Diego, 10240 Sorrento Valley Road - Ouvert sur google cards, Cartes yandex ouvertes
Site web: https://www.atyrpharma.com

À propos de l'entreprise aTyr Pharma, Inc.

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.